Aquestive Therapeutics vs Aytu Biopharma
Aytu Biopharma is the larger business, with $57.6m of revenue in fiscal 2026 against $44.5m for Aquestive Therapeutics (1.3 times as much). Aytu Biopharma grew faster (-13.3% against -22.6%). Aytu Biopharma kept more of each dollar of sales as profit: a net margin of -24.8% against -188.1%.
| Latest fiscal year | Aquestive TherapeuticsAQST, 2025 | Aytu BiopharmaAYTU, 2026 |
|---|---|---|
| Revenue | $44.5m | $57.6m |
| Revenue growth | -22.6% | -13.3% |
| Net income | −$83.8m | −$14.3m |
| Operating margin | -159.5% | — |
| Net margin | -188.1% | -24.8% |
| Return on equity | — | -52.6% |
| Free cash flow | −$53.0m | $3.3m |
| Cash | $121m | $26.3m |
| Total debt | $55.0m | $17.0m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 147 | 76 |
| Market value | $485m | $20.8m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 0 sales |